Status:
RECRUITING
Effect of Semaglutide in Patients With Psoriasis and Obesity
Lead Sponsor:
The University of Hong Kong
Conditions:
Psoriasis (PsO)
Obesity and Overweight
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics. Weight loss can lead ...
Eligibility Criteria
Inclusion
- a clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent.
- Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception
- \>18 years of age, up to 75 years of age
- Adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
- Moderate to severe psoriasis (PASI score 5-10= moderate, \>10 = severe)
- Chinese ethnicity
- On stable dose of standard treatment
- Ability to comply with stud
Exclusion
- Patients who refuse to give consent
- Contraindication to use of GLP1 RA
- History of pancreatitis
- History of MEN / MTC
- Known hypersensitivity to semaglutide or excipients in semaglutide
- Type 1 diabetes
- Gallbladder disease
- Active malignancy or History of malignancy within 5 years
- Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals within 4 weeks before baseline visit
- Pregnancy or breastfeeding, subjects should inform their healthcare provider of a known or suspected pregnancy
- History of allergic reaction assessed as related to investigational product by the investigator
- Major psychiatric illness
- Treatment with live/ attenuated vaccine within the last 28 days prior to randomisation
- History of alcohol or substance abuse within 6 months prior to initial screening
- Patients with a history of suicidal attempts or active suicidal ideation
Key Trial Info
Start Date :
March 20 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT06937060
Start Date
March 20 2025
End Date
January 31 2027
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Hong Kong, Department of Medicine
Hong Kong, Hong Kong